[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cejas et al., 2012 - Google Patents

Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy

Cejas et al., 2012

Document ID
11269280997601721935
Author
Cejas P
Lopez-Gomez M
Aguayo C
Madero R
Moreno-Rubio J
de Castro Carpeno J
Belda-Iniesta C
Barriuso J
Moreno Garcia V
Diaz E
Burgos E
Gonzalez-Baron M
Feliu J
Publication year
Publication venue
Current cancer drug targets

External Links

Snippet

Patients with metastatic Colorectal Cancer (mCRC), in which primary tumors are KRAS mutated, have no response to anti-EGFR therapy. However, less than half of mCRC patients with KRAS wild-type primary tumors respond to anti-EGFR therapy. Other downstream …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Cejas et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy
Bardelli et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
Watson et al. Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance
US20220213219A1 (en) Bruton's Tyrosine Kinase as Anti-Cancer Drug Target
Park et al. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
Tamborini et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
JP2018508183A (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancer
Projetti et al. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas
US10442862B2 (en) Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
WO2014028222A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
JP2018516870A (en) Method for treating a patient having a mutation in the extracellular domain of epidermal growth factor receptor (EGFR) using a combination of three fully human monoclonal anti-EGFR antibodies
JP2017526916A (en) Diagnosis of cancer
CN110225984A (en) Identify the method and therapeutic choice of risk of cancer
EP4291902A2 (en) Biomarkers for cancer treatment
EP3722417A1 (en) Cancer spheroid production method and method for selecting colon cancer patients
WO2014145254A2 (en) Falz for use as a target for therapies to treat cancer
Isobe et al. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
US20160206646A1 (en) Bruton's Tyrosine Kinase as Anti-Cancer Drug Target
WO2023137447A1 (en) Alk gene fusions and uses thereof
CN105188742A (en) Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
Wang et al. GEFT protein expression in digestive tract malignant tumors and its clinical significance
Felsberg et al. Prognostic role of epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas
Emmerich VCAN Accumulation and Proteolysis Play Critical Roles in Directing CD8+ TILs and Response to ICIs in Solid Tumors
US20150218647A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
Zhang et al. MiR-323a-3p Inhibits Tumor Growth and Gefitinib Resistance Acquisition by Targeting EGFR/ErbB3 in Colorectal Cancer